Nutlin-3a

Catalog No.S8059

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.

Price Stock Quantity  
USD 197 In stock
USD 670 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Nutlin-3a Chemical Structure

Nutlin-3a Chemical Structure
Molecular Weight: 581.49

Validation & Quality Control

Quality Control & MSDS

Product Information

  • Compare Mdm2 Inhibitors
    Compare Mdm2 Products
  • Research Area

Product Description

Biological Activity

Description Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.
Targets p53/MDM2 interaction [3]
(Cell-free assay)
IC50 90 nM
In vitro Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
MV-4-11M2jOTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2m1VWlEPTB;MD62NVI{PyEQvF2=NYXwdFR4W0GQR1XS
H4NHHoTVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2S5WmlEPTB;MD62OlI5KM7:TR?=MYXTRW5ITVJ?
PA-1NUjwbVVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\HV3pKSzVyPUCuPFcxQTZizszNM2\tOnNCVkeHUh?=
NKM-1MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2fmV2lEPTB;MT6wOFk{OSEQvF2=Ml\iV2FPT0WU
NEC8M1TRNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoTWTWM2OD1zLkKxOVczKM7:TR?=MVHTRW5ITVJ?
EoL-1-cellMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{nsd2lEPTB;MT6yOlcxOSEQvF2=M{W2fXNCVkeHUh?=
K5NEK5TZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYTjdnhOUUN3ME2xMlQzODd{IN88US=>NV32SIxDW0GQR1XS
QIMR-WILMlTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTFwNkC4OVQh|ryPMlf0V2FPT0WU
MOLT-16Mo\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkL1TWM2OD1zLke4OlA1KM7:TR?=MXzTRW5ITVJ?
CHP-212MnW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M174UGlEPTB;MT64NVM3QSEQvF2=MnTGV2FPT0WU
CTB-1Ml7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3LoVWlEPTB;Mj6wNlI1PiEQvF2=NVLyPHpHW0GQR1XS
MOLT-4Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTQdY81UUN3ME2yMlMzQDV|IN88US=>MoDkV2FPT0WU
A101DM{TmNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUnJR|UxRTJwM{WwNUDPxE1?NGnw[GtUSU6JRWK=
DOHH-2M{TvPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUnJR|UxRTJwNEKyO|kh|ryPMU\TRW5ITVJ?
ES4NGfsUodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTJwNEOxOVUh|ryPM3rLXHNCVkeHUh?=
SW780NUe1ZXp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWrJR|UxRTJwNUC4PFMh|ryPMlLDV2FPT0WU
VA-ES-BJM2X3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEHwOHFKSzVyPUKuOVQyOSEQvF2=MkDkV2FPT0WU
RPMI-8866NWn4OGZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{DQNGlEPTB;Mj61OlIyPCEQvF2=M4HacnNCVkeHUh?=
ML-2NFzXRnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUDJR|UxRTJwNU[1O|Yh|ryPMn72V2FPT0WU
MSTO-211HNVm0XpNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFPkTYFKSzVyPUKuOVc1PTFizszNNHOySXRUSU6JRWK=
JVM-3NGPSbo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXzJR|UxRTJwNUmzNlQh|ryPNXr6Z4VWW0GQR1XS
A3-KAWNXrRZXlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTJwNkG4NVgh|ryPNGX4OJRUSU6JRWK=
DK-MGM4Dkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlPCTWM2OD1{Lk[yOFcyKM7:TR?=NUHiXnNsW0GQR1XS
LNCaP-Clone-FGCMkPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1GycGlEPTB;Mj62OFMyQCEQvF2=M2LtT3NCVkeHUh?=
HT-144NYjrVZFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MofpTWM2OD1{Lk[0OVc4KM7:TR?=MVHTRW5ITVJ?
NB69NHLwOVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVPJR|UxRTJwNkWzN|Qh|ryPM1zaVnNCVkeHUh?=
A172M2jpZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlzFTWM2OD1{Lk[3OVg5KM7:TR?=NFHSOIpUSU6JRWK=
RS4-11NX7MNoppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlPzTWM2OD1{LkeyOFA4KM7:TR?=NIfNcYtUSU6JRWK=
DU-4475NIPocWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2PYUWlEPTB;Mj63PVUxOiEQvF2=M{CzUXNCVkeHUh?=
SJSA-1MojKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTJwOEK1OVYh|ryPMlj4V2FPT0WU
BV-173NGfwRYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkLVTWM2OD1{Lki0OFM6KM7:TR?=MmDtV2FPT0WU
U-2-OSNHLpXIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTJwOUGwO{DPxE1?NUjKSmh4W0GQR1XS
CHP-134NYXrdo5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYfzOnlMUUN3ME2yMlk{QDh{IN88US=>NH;ZVmhUSU6JRWK=
D-502MGNHfNR4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTJwOUexOVQh|ryPNG\qVHJUSU6JRWK=
KS-1NWTIPXMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk[yTWM2OD1|LkCxOlI{KM7:TR?=MlvCV2FPT0WU
A204NXPjPHE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWPxPXBvUUN3ME2zMlA2PTh6IN88US=>M4jU[HNCVkeHUh?=
KGNMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTNwMEi0PVYh|ryPNIWw[lJUSU6JRWK=
NCI-H292NVzMUXUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfBTWM2OD1|LkGyNFI5KM7:TR?=NW\ubooxW0GQR1XS
CAKI-1M3e2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTNwMUK2PVQh|ryPNI\nZm1USU6JRWK=
C2BBe1MnLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYPnV5NvUUN3ME2zMlE4ODJ4IN88US=>NWr0Xll4W0GQR1XS
NB10NXzZT2pnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEn5VIJKSzVyPUOuNlA6PjZizszNMYjTRW5ITVJ?
MHH-NB-11NX3zNJFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVTOfmJxUUN3ME2zMlI3QDJ5IN88US=>NVPPfVZRW0GQR1XS
NCI-SNU-1M2nJ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHKyXJlKSzVyPUOuNlc5PDNizszNMlzmV2FPT0WU
HCT-116MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYrE[GxRUUN3ME2zMlMxOzN3IN88US=>Ml73V2FPT0WU
G-401NWjaenRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUjncXhCUUN3ME2zMlM3OzJ{IN88US=>NFq4VGxUSU6JRWK=
MN-60MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1jpNmlEPTB;Mz60OFA6OiEQvF2=MonLV2FPT0WU
SW982MmfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mlv0TWM2OD1|LkWwPFQ5KM7:TR?=M37TOHNCVkeHUh?=
RKONH70So5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnTXTWM2OD1|LkWzPVM3KM7:TR?=MlrJV2FPT0WU
D-283MEDMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEn5Z|RKSzVyPUOuOVc6QDZizszNMVzTRW5ITVJ?
LB996-RCCNUnCU|UyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mlu1TWM2OD1|Lk[yOVU5KM7:TR?=NVXqXmZ4W0GQR1XS
A549NE\vPIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoCyTWM2OD1|Lk[zOVUzKM7:TR?=M33jRXNCVkeHUh?=
LB2241-RCCM2fRZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTNwNkW3NFgh|ryPNVTQPHhIW0GQR1XS
SK-HEP-1MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEn6fY9KSzVyPUOuO|QzQTdizszNM2PQenNCVkeHUh?=
G-402M2XLfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1PsOWlEPTB;Mz64NFg{OiEQvF2=MmG4V2FPT0WU
GOTONGKwXItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIXPVZFKSzVyPUOuPFQ{OzNizszNNE\lbJlUSU6JRWK=
LOXIMVINGXGW2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWnJR|UxRTNwOEW2O|Uh|ryPNFX3WIFUSU6JRWK=
NH-12MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{e3PGlEPTB;ND6wNVk2QSEQvF2=NGPFS3JUSU6JRWK=
CTV-1NGPtN|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEHGPXpKSzVyPUSuNFc6PzNizszNMUHTRW5ITVJ?
CP50-MEL-BMmHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTRwMkSzPVIh|ryPM1LaNnNCVkeHUh?=
RH-18NHvQPGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWq3UZU{UUN3ME20MlI4PzB4IN88US=>MoXOV2FPT0WU
NB17NEHiOWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIjFbllKSzVyPUSuN|E4PjhizszNM1jMWXNCVkeHUh?=
A375NHy4d4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTRwM{O1NlQh|ryPNVrQRXB[W0GQR1XS
IST-MES1MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWDJR|UxRTRwNEG0NVEh|ryPNVfmeYRFW0GQR1XS
MZ2-MELNYHlVVNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTRwNUCxOVUh|ryPNX70S2xmW0GQR1XS
CAL-54NUTUPXExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\XTWM2OD12LkWzNFE6KM7:TR?=MV\TRW5ITVJ?
NCI-H28NGnBSFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWPO[VY2UUN3ME20MlYzPzF5IN88US=>MYrTRW5ITVJ?
D-247MGNHe0WXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnO4TWM2OD12Lke1NFczKM7:TR?=NEHyVGVUSU6JRWK=
NCI-H460M2\DXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH;md2lKSzVyPUSuPVEyOjdizszNMle5V2FPT0WU
MCF7NYTqNYJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTVwNESyOFQh|ryPMn\oV2FPT0WU
697M4TGSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3jZTGlEPTB;NT60OFU2KM7:TR?=MU\TRW5ITVJ?
ONS-76Ml:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1e2emlEPTB;NT61O|AxQSEQvF2=MUjTRW5ITVJ?
C32NVjCfFFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTVwNkCwNlkh|ryPM3nYNHNCVkeHUh?=
OS-RC-2NHfw[5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYOzc3NUUUN3ME21Mlc{QDh5IN88US=>MWTTRW5ITVJ?
MEL-HOMo\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTVwOEW2Olch|ryPM{TqSHNCVkeHUh?=
LoVoM2roVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MojoTWM2OD14LkCxOlI1KM7:TR?=M1\oZnNCVkeHUh?=
AGSM1vkNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTZwMUS4Nlgh|ryPNXXGVmd7W0GQR1XS
GI-ME-NNEPF[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXnJR|UxRTZwMkK0NlEh|ryPM2LwdHNCVkeHUh?=
H-EMC-SSNV\NRoxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfYTWM2OD14LkO4OkDPxE1?NIe0V2xUSU6JRWK=
RVH-421NYfGfWpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MljYTWM2OD14LkSyOFI5KM7:TR?=M3j6SHNCVkeHUh?=
SW954NWXxWlNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFLJRldKSzVyPU[uOVU2PzJizszNM3T3eXNCVkeHUh?=
NB5MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVPwNG1OUUN3ME22MlU3OTh|IN88US=>MVLTRW5ITVJ?
NCI-H2122MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEXpeohKSzVyPU[uOVg4QTNizszNNUP4S3ZpW0GQR1XS
AM-38M4LVeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE[wdIxKSzVyPU[uO|U3OzlizszNNWjjT2NoW0GQR1XS
KNS-81-FDNWS3XphKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWXrOZJmUUN3ME22Mlc3PDl2IN88US=>NWr3S5g5W0GQR1XS
LS-513NVTyUll3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHz0VHNKSzVyPU[uO|kxOjZizszNMXvTRW5ITVJ?
A427M3zoXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn7PTWM2OD14Lki3PFI6KM7:TR?=NVXNVolGW0GQR1XS
WM-115M13pZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NULMcXNJUUN3ME22Mlk{OjNizszNM3rOdXNCVkeHUh?=
COLO-829M1G1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmDETWM2OD15LkK0NVg5KM7:TR?=MVjTRW5ITVJ?
NCI-H1650NG\kTVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVvlSIJyUUN3ME23MlM6OjJ6IN88US=>M3LNeXNCVkeHUh?=
NCI-H358M{XkNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vsSmlEPTB;Nz60OFg4QSEQvF2=MXfTRW5ITVJ?
HT-1080NXzSdm0zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYHJR|UxRTdwNEiyOVQh|ryPNFHnPHpUSU6JRWK=
HCC2218NHnGcYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1mxfGlEPTB;Nz62Nlk4KM7:TR?=MUnTRW5ITVJ?
NCI-H661NVL2fpV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTdwOEewOlkh|ryPMWrTRW5ITVJ?
KM-H2MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRTdwOEi2PVQh|ryPMVPTRW5ITVJ?
RPMI-2650NH3KbW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn3wTWM2OD15Lkm0OFE1KM7:TR?=NF\aSlJUSU6JRWK=
NCI-H226NYXJZ4xzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRThwMkGxNlIh|ryPMX\TRW5ITVJ?
MKN45NYnxNo1MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRThwMk[2NFIh|ryPMUPTRW5ITVJ?
D-392MGNYrjWGlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIezZnNKSzVyPUiuOVI4OjJizszNNVfTR4RuW0GQR1XS
RCC10RGBMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlKxTWM2OD16Lki2Olk2KM7:TR?=M3fkN3NCVkeHUh?=
CAL-51MlLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\1TWM2OD17LkGwNlUyKM7:TR?=MnvJV2FPT0WU
COLO-678M1n1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH3WTJFKSzVyPUmuN|I5OTFizszNMXfTRW5ITVJ?
SK-MEL-24NYPYW441T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVvTRW4yUUN3ME25MlU2QDV4IN88US=>M4nyPHNCVkeHUh?=
SK-MEL-30M{XMO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXzmVXczUUN3ME25Mlk1PDd4IN88US=>NXj2W5RDW0GQR1XS
MMAC-SFNUfqenNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIezeHRKSzVyPUGwMlM6PjFizszNNFLQRZpUSU6JRWK=
NTERA-S-cl-D1MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTFyLk[1NFgh|ryPNVzBc4VWW0GQR1XS
NB12MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{LoV2lEPTB;MUGuOVA{KM7:TR?=MWXTRW5ITVJ?
UACC-257Mn3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIHqSndKSzVyPUGxMlg3QTVizszNMmrDV2FPT0WU
LAN-6M3;BXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37SSWlEPTB;MUGuPVkzQCEQvF2=NFuwb5NUSU6JRWK=
SW1573M1nMVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVzJR|UxRTF{LkOwPFYh|ryPM33XbXNCVkeHUh?=
NMC-G1NHfnPJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHnBRWtKSzVyPUGyMlQyPzVizszNNX\DV4hbW0GQR1XS
SHP-77MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoLRTWM2OD1zMj61OVc1KM7:TR?=NEHhbodUSU6JRWK=
IGROV-1NH;EeZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnvBTWM2OD1zMj62OVc{KM7:TR?=M1;JUXNCVkeHUh?=
22RV1MnjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkPsTWM2OD1zMj64NFU6KM7:TR?=NXL6UZRyW0GQR1XS
SK-MEL-3NFLWZ3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTF|LkO5O|Mh|ryPNYfJUpVXW0GQR1XS
NCI-H1563MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFH5UGFKSzVyPUGzMlQzODJizszNM4frWnNCVkeHUh?=
IGR-1NVe3[3FpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33UXmlEPTB;MUSuNFM1PyEQvF2=MYXTRW5ITVJ?
EW-3MmrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYLJR|UxRTF2LkG2N|kh|ryPNXfrWohWW0GQR1XS
JEG-3MmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTF2LkS5OVMh|ryPMWrTRW5ITVJ?
ES3MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTF2Lk[1OlIh|ryPMlXYV2FPT0WU
MDA-MB-175-VIIMlvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFm4UXJKSzVyPUG0MlcyOTFizszNMW\TRW5ITVJ?
P30-OHKM2XWeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWexOI9EUUN3ME2xOU4xPDl4IN88US=>NHW3TpZUSU6JRWK=
GP5dM3TyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXTJR|UxRTF3LkG0OlYh|ryPMnriV2FPT0WU
HMV-IIMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjITWM2OD1zNT6zN|M{KM7:TR?=MoW1V2FPT0WU
COLO-679NYDyW|VsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXXiW4VHUUN3ME2xOU42ODFizszNM4TzU3NCVkeHUh?=
JARM1nlPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3nTfWlEPTB;MUWuO|IxPSEQvF2=NIjTTYJUSU6JRWK=
NCI-H1666Mlf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUjRRZZCUUN3ME2xOU46Ozl7IN88US=>MUHTRW5ITVJ?
SW48NGXoO2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFmwZ3JKSzVyPUG1Mlk2OTZizszNMknCV2FPT0WU
NCI-H720M{nnfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTF3Lkm5PFkh|ryPMljQV2FPT0WU
HT-1197M2P2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTF4LkCzOVIh|ryPMUDTRW5ITVJ?
HL-60M3fQ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTF4LkCzPFQh|ryPM2S4TXNCVkeHUh?=
BENNXy5S3BLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXzJR|UxRTF4LkW2N|gh|ryPMVXTRW5ITVJ?
HAL-01NITlbIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGfFbnVKSzVyPUG2Mlg6ODlizszNNWHhb2xGW0GQR1XS
SW900MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV3Z[ZVJUUN3ME2xOk46OTN{IN88US=>MnfmV2FPT0WU
SBC-1M1mwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2fES2lEPTB;MUeuOVQzQSEQvF2=MmXUV2FPT0WU
SH-4Mo\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTF5LkW4OFEh|ryPM37t[3NCVkeHUh?=
UACC-62MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTF5Lke2N|ch|ryPM4XETHNCVkeHUh?=
BHT-101MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTF7Lki3NFUh|ryPMlnpV2FPT0WU
DBMkf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV7XeGsyUUN3ME2yNU42PjR7IN88US=>MUnTRW5ITVJ?
SK-MEL-1NFX0eZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2DlS2lEPTB;MkGuOVg4OiEQvF2=M3u0SnNCVkeHUh?=
NCI-H747NXnybJM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoLITWM2OD1{Mj63N|c6KM7:TR?=Mn31V2FPT0WU
SK-LU-1NH7FcG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmfCTWM2OD1{Mz6zOVI1KM7:TR?=M1fq[XNCVkeHUh?=
KG-1NFuwTm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1TMfWlEPTB;MkOuOFk1PiEQvF2=M4qyOHNCVkeHUh?=
LXF-289NGrGcVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIm4WoZKSzVyPUKzMlcyPCEQvF2=MmXJV2FPT0WU
HCC1954Moi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTJ2Lki4OFQh|ryPMkLQV2FPT0WU
Ramos-2G6-4C10NFq3fnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYHJR|UxRTJ4LkS5PFEh|ryPM2rpVHNCVkeHUh?=
DBTRG-05MGMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDFSHdKSzVyPUK2MlY1QDhizszNM3TPb3NCVkeHUh?=
NCI-H2052MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTJ5LkW2PFQh|ryPNIrTdIFUSU6JRWK=
RMG-INUToW4JzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn6yTWM2OD1{OT60NVM6KM7:TR?=Mk\BV2FPT0WU
H9MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEniendKSzVyPUOxMlMxODhizszNNWHrd2Y3W0GQR1XS
GR-STNY\3UFFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3MOZZkUUN3ME2zNk41PDV|IN88US=>MnvkV2FPT0WU
Mo-TM2n5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWe4N29RUUN3ME2zNk42ODR4IN88US=>M2XhdHNCVkeHUh?=
SW1088NVKy[pZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{PZOmlEPTB;M{KuPVgxOSEQvF2=MWfTRW5ITVJ?
LB2518-MELNV\VUotlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4\hdGlEPTB;M{OuNFc6PyEQvF2=MkOwV2FPT0WU
NCI-H82MkfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoX3TWM2OD1|Mz6xOlYyKM7:TR?=NI[yUW1USU6JRWK=
LAMA-84NVe0VJo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1z6cmlEPTB;M{SuOlA4OyEQvF2=NXLJVVl6W0GQR1XS
KYSE-450NXHYSnROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTN2Lk[3O|Yh|ryPM2W4NnNCVkeHUh?=
LU-99ANH;tPJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;OdYdiUUN3ME2zOU4xODB5IN88US=>M2jafnNCVkeHUh?=
BE-13NYPmfXAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTN3Lk[1OFUh|ryPNH;vSW9USU6JRWK=
GAKM{PlSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\vWJlMUUN3ME2zOU43QTVizszNM1vyc3NCVkeHUh?=
NCI-H1573NWHETVhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfhWmlKSzVyPUO1Mlg5OThizszNMn3uV2FPT0WU
AsPC-1MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnvyTWM2OD1|Nj6xOVI4KM7:TR?=Ml22V2FPT0WU
HDLM-2M33UNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF3MfHRKSzVyPUO2MlMyPiEQvF2=MXXTRW5ITVJ?
NCI-H441MojRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnvITWM2OD1|Nz6wOlkyKM7:TR?=NIj5XllUSU6JRWK=
CAL-27NGCzTIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\ue|VCUUN3ME2zO{44OjNzIN88US=>NWPCRnpNW0GQR1XS
OVCAR-3MoX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUfVOo55UUN3ME2zPU4{OThzIN88US=>MlvWV2FPT0WU
RPMI-8226NFX5RXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkDjTWM2OD1|OT61PVgh|ryPNVf2boxUW0GQR1XS
EFO-21M2PJWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3raNGlEPTB;NECuOVgyPCEQvF2=M33SOnNCVkeHUh?=
SNU-C2BNEDqO4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlrvTWM2OD12MT61NFg1KM7:TR?=MlT3V2FPT0WU
VM-CUB-1MlXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYXnNm5xUUN3ME20N{45ODN5IN88US=>NHfPW3FUSU6JRWK=
NCI-H2087MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUPVfmcyUUN3ME20OU4xOjN|IN88US=>MmPTV2FPT0WU
EW-16NH;hVHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NY\hWlg3UUN3ME20Ok4{OTN5IN88US=>MUHTRW5ITVJ?
SK-N-ASMnXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1Hkc2lEPTB;NE[uO|E3PyEQvF2=NUnnS5RxW0GQR1XS
COR-L105NXi3dZVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTR4Lki4OVch|ryPMl\RV2FPT0WU
DELM2HsTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUL4SnAzUUN3ME20PE4xPDJ7IN88US=>NIjXZpFUSU6JRWK=
JVM-2NWr5NYY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\XTWM2OD12OD6wOVU5KM7:TR?=NF7pdVdUSU6JRWK=
KARPAS-45MlzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3;QV2lEPTB;NEmuOFU{QCEQvF2=MkHUV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.

Protocol(Only for Reference)

Kinase Assay: [3]

Biacore studies Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of inhibitor is calculated as a percentage of binding in the absence of inhibitor and IC50 is calculated using Microsoft Excel

Cell Assay: [2]

Cell lines OSA, T778, RMS13, U2OS, SaOS-2
Concentrations ~5 μM
Incubation Time 120 h
Method SRB

Animal Study: [1]

Animal Models SJSA-1 xenograft
Formulation 1% Klucel, 0.1% Tween 80
Dosages 50, 100, 200 mg/kg twice daily
Administration oral

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Tovar C, et al. Proc Natl Acad Sci U S A, 2006, 103(6), 1888-1893.

[2] Ohnstad HO, et al. BMC Cancer, 2011, 11(211), 1-11.

view more

Chemical Information

Molecular Weight (MW) 581.49
Formula

C30H30Cl2N4O4

CAS No. 675576-98-4
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms (-)-Nutlin-3
Solubility (25°C) * In vitro DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water <1 mg/mL (<1 mM)
In vivo 2% DMSO+1% hydroxyethyl cellulose+0.2% Tween 80 15 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2-Piperazinone, 4-[[(4S,5R)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Mdm2 Products

  • Idasanutlin (RG-7388)

    Idasanutlin (RG-7388) is a potent and selective p53-MDM2 inhibitor with IC50 of 6 nM.

  • MI-773 (SAR405838)

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • A-1210477

    A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

  • Nutlin-3

    Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

  • NSC 207895

    NSC 207895 suppresses MDMX with IC50 of 2.5 μM, leading to enhanced p53 stabilization/activation and DNA damage, and also regulates MDM2, an E3 ligase.

  • Nutlin-3b

    Nutlin-3b is a p53/MDM2 antagonist or inhibitor with IC50 value of 13.6 μM, 150-fold less potent (+)-enantiomer of Nutlin-3 as in comparison with opposite (-)-enantiomer Nutlin-3a.

  • YH239-EE

    YH239-EE, the ethyl ester of YH239, is a potent p53-MDM2 antagonist and an apoptosis inducer.

  • Z-VAD-FMK

    Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

    Features:A key compound for apoptosis studies.

  • ABT-263 (Navitoclax)

    ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

    Features:Re-engineered version of ABT-263 (Navitoclax).

Recently Viewed Items

Tags: buy Nutlin-3a | Nutlin-3a supplier | purchase Nutlin-3a | Nutlin-3a cost | Nutlin-3a manufacturer | order Nutlin-3a | Nutlin-3a distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us